Excision Repair Cross-complementing Group-1 (ERCC1) Induction and Polymorphism are Markers of inferior outcome in Patients with Colorectal Cancer Treated with Oxaliplatin

Santiago Aparo; Devika Rao; A. B. Mallick; T. Augustine; C. Daroqui; J. Jiffry; A. Merla

Excision Repair Cross-complementing Group-1 (ERCC1) Induction and Polymorphism are Markers of inferior outcome in Patients with Colorectal Cancer Treated with Oxaliplatin

Santiago Aparo, Devika Rao, A. B. Mallick, T. Augustine, C. Daroqui, J. Jiffry, A. Merla

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Cancer Research. Proceedings. / American Cancer Association for Cancer Research. Annual Meeting
Volume	79
State	Published - 2019

Disciplines

Medicine and Health Sciences

Cite this

Excision Repair Cross-complementing Group-1 (ERCC1) Induction and Polymorphism are Markers of inferior outcome in Patients with Colorectal Cancer Treated with Oxaliplatin. / Aparo, Santiago; Rao, Devika; Mallick, A. B. et al.
In: Cancer Research. Proceedings. / American Cancer Association for Cancer Research. Annual Meeting, Vol. 79, 2019.

Research output: Contribution to journal › Article › peer-review

@article{3def37c64bdf444ca7799f26718aea67,

title = "Excision Repair Cross-complementing Group-1 (ERCC1) Induction and Polymorphism are Markers of inferior outcome in Patients with Colorectal Cancer Treated with Oxaliplatin",

author = "Santiago Aparo and Devika Rao and Mallick, \{A. B.\} and T. Augustine and C. Daroqui and J. Jiffry and A. Merla",

note = "Abstract. Background: Oxaliplatin confers tumoricidal effect by forming platinum-DNA adducts and is an integral part of the treatment paradigm for patients with colorectal cancer (CRC). The nucleotide excision repair pathway (NERP) plays a crucial role in tissue resistance to the drug.",

year = "2019",

language = "American English",

volume = "79",

journal = "Cancer Research. Proceedings. / American Cancer Association for Cancer Research. Annual Meeting",

}

TY - JOUR

T1 - Excision Repair Cross-complementing Group-1 (ERCC1) Induction and Polymorphism are Markers of inferior outcome in Patients with Colorectal Cancer Treated with Oxaliplatin

AU - Aparo, Santiago

AU - Rao, Devika

AU - Mallick, A. B.

AU - Augustine, T.

AU - Daroqui, C.

AU - Jiffry, J.

AU - Merla, A.

N1 - Abstract. Background: Oxaliplatin confers tumoricidal effect by forming platinum-DNA adducts and is an integral part of the treatment paradigm for patients with colorectal cancer (CRC). The nucleotide excision repair pathway (NERP) plays a crucial role in tissue resistance to the drug.

PY - 2019

Y1 - 2019

UR - https://aacrjournals.org/cancerres/article/79/13_Supplement/4932/636439/Abstract-4932-Excision-repair-cross-complementing

M3 - Article

VL - 79

JO - Cancer Research. Proceedings. / American Cancer Association for Cancer Research. Annual Meeting

JF - Cancer Research. Proceedings. / American Cancer Association for Cancer Research. Annual Meeting

ER -

Excision Repair Cross-complementing Group-1 (ERCC1) Induction and Polymorphism are Markers of inferior outcome in Patients with Colorectal Cancer Treated with Oxaliplatin

Disciplines

Other files and links

Cite this